A Prospective, Observational Study of Patients With Fabry Disease (US Specific)

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

CT.gov Identifier

NCT06906367

EudraCT Identifier

N/A

CTIS:

N/A

Collaborator

N/A

Study Contact Information

+1 609 662 2000

Recruiting

Study Details

Diseases

Fabry Disease

Study Drug

Migalastat hydrochloride

Enzyme replacement therapy, unspecified

Genes

GLA

Study Dates

Feb 2026 - Jun 2032

Sex

Female & Male

Age

18+ years

Inclusion and Exclusion Criteria

Inclusion Criteria:

I. Migalastat-treated patients (Commercial only participants)
1. Patients with Fabry disease 18 years or older with amenable GLA variants who have commenced commercial migalastat treatment within 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment and are still taking migalastat at the time of enrollment, or who are starting migalastat at the time of enrollment, excluding those who participated in a prior migalastat clinical trial
2. Patients who show a decline in their Fabry disease symptomatology based on any of the following:
1. a decrease in annualized rate of decline eGFRCKD-EPI of ≥ 2 mL/min/1.73 m2 during the 2 years prior to enrollment
2. microalbuminuria/macroalbuminuria (≥ 30 mg/24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg/g (via spot urine collection) at any time prior to or at enrollment
3. proteinuria (\> 0.5 g/g UPCR) any time prior to or at enrollment
4. males with classic Fabry disease phenotype
II. Migalastat-treated patients who are not considered to be in renal decline (Commercial migalastat users only)
1. Patients with Fabry disease with amenable GLA variants who have been on commercial migalastat regardless of the duration of treatment
III. Migalastat-treated patients (Prior clinical trial participants)
1. Patients with Fabry disease 18 years or older who had commenced treatment with migalastat while in a clinical trial and were exposed to treatment for at least 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment, and who are still taking migalastat at the time of enrollment, having switched to commercial product
IV. Untreated patients
1. Patients with Fabry disease 18 years or older with amenable GLA variants, who have never been on treatment for Fabry disease, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment, and who meet local treatment guidelines for Fabry disease
2. Patients who show a decline in their Fabry disease symptomatology based on any of the following:
1. a decrease in annualized rate of decline eGFRCKD-EPI of ≥ 2 mL/min/1.73 m2 during the 2 years prior to enrollment
2. microalbuminuria/macroalbuminuria (≥ 30 mg/24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg/g (via spot urine collection) at any time prior to or at enrollment
3. proteinuria (\> 0.5 g/g UPCR) any time prior to or at enrollment
4. males with classic Fabry disease phenotype
V. ERT-treated patients
1. Patients with Fabry disease 18 years or older who have commenced ERT within 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment and are still being treated with ERT at the time of enrollment, and who have amenable GLA variants
2. Patients who show a decline in their Fabry disease symptomatology based on any of the following:
1. a decrease in eGFRCKD-EPI annualized rate of decline of ≥ 2 mL/min/1.73 m2 during the 2 years prior to enrollment
2. microalbuminuria/macroalbuminuria (≥ 30 mg/24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg/g (via spot urine collection) at any time prior to or at enrollment
3. proteinuria (\> 0.5 g/g UPCR) any time prior to or at enrollment
4. males with classic Fabry disease phenotype
All patients 1. All treated and untreated patients with Fabry disease who are enrolled in the study must be able to understand and provide written informed consent or assent.

Exclusion Criteria:

1\. Patients who currently are participating in a clinical trial of any investigational medicinal product or device at the time of enrollment

Protocol Summary

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.

Fields marked with asterisk (*) are mandatory.